Vienna experience of ABO-incompatible living-donor kidney transplantation
- PMID: 19562281
- DOI: 10.1007/s00508-009-1161-3
Vienna experience of ABO-incompatible living-donor kidney transplantation
Abstract
ABO-incompatible kidney transplantation is a promising strategy for enlargement of living-donor pools. In recent years, recipient desensitization by blood group antigen-specific immunoadsorption, together with rituximab and intravenous immunoglobulin, has allowed excellent graft performance after ABO-incompatible transplantation. Adopting this protocol, originally described by Tydén and coworkers, we performed four living-donor renal transplants across the ABO barrier (A1-->0, A1-->B, B-->A1, A2-->0) between July 2007 and August 2008. Recipients were aged 25-66 years, donors 49-69 years. A protocol of on-demand immunoadsorption was followed, based on serial post-transplant antibody monitoring. Substantial and sustained decrease of blood group antibody levels was achieved in all four recipients, therefore post-transplant immunoadsorption was not needed. Graft and patient survival after 4-18 months' follow-up was 100%. Current serum creatinine was 1.3-2.0 mg/dl. Two grafts showed C4d deposits in peritubular capillaries in the complete absence of typical morphological features of antibody-mediated rejection. One recipient experienced early graft dysfunction, diagnosed as Banff borderline lesion, which responded well to steroid pulse therapy. The same recipient developed de novo interstitial fibrosis/tubular atrophy and arteriolar hyalinosis, presumably the result of suboptimal control of blood pressure and/or calcineurin inhibitor therapy. Two of the four recipients developed lymphoceles necessitating surgical revision. Apart from urinary tract infection in three patients and subclinical CMV in one, no major infectious complications were reported. Notably, two stable recipients developed polyoma BK viremia without clinical or morphological manifestations of polyomavirus-associated nephropathy. The results obtained in our small series support the earlier reported high efficiency of desensitization based on antigen-specific immunoadsorption. Nevertheless, the lack of long-term data will necessitate continuous and prudent consideration of the benefits and risks of this strategy.
Comment in
-
ABO-incompatible kidney transplantation.Wien Klin Wochenschr. 2009;121(7-8):227-9. doi: 10.1007/s00508-009-1165-z. Wien Klin Wochenschr. 2009. PMID: 19562277 No abstract available.
Similar articles
-
ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment.Xenotransplantation. 2006 Mar;13(2):148-53. doi: 10.1111/j.1399-3089.2006.00280.x. Xenotransplantation. 2006. PMID: 16623810
-
Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation.Transpl Int. 2014 Feb;27(2):187-96. doi: 10.1111/tri.12234. Epub 2013 Dec 28. Transpl Int. 2014. PMID: 24188566
-
Desensitization with plasmapheresis and anti-Cd20 for ABO incompatible kidney transplantation from living donor: experience of a single center in Italy.Transplant Proc. 2014 Sep;46(7):2209-13. doi: 10.1016/j.transproceed.2014.07.063. Transplant Proc. 2014. PMID: 25242753
-
Isoagglutinin adsorption in ABO-incompatible transplantation.Transfus Apher Sci. 2010 Oct;43(2):231-5. doi: 10.1016/j.transci.2010.07.016. Epub 2010 Jul 27. Transfus Apher Sci. 2010. PMID: 20667787 Review.
-
Probable C4d-negative accelerated acute antibody-mediated rejection due to non-HLA antibodies.Nephrology (Carlton). 2015 Jul;20 Suppl 2:75-8. doi: 10.1111/nep.12467. Nephrology (Carlton). 2015. PMID: 26031592 Review.
Cited by
-
ABO-incompatible kidney transplantation.Wien Klin Wochenschr. 2009;121(7-8):227-9. doi: 10.1007/s00508-009-1165-z. Wien Klin Wochenschr. 2009. PMID: 19562277 No abstract available.
-
Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients.Clin J Am Soc Nephrol. 2012 Aug;7(8):1320-7. doi: 10.2215/CJN.00770112. Epub 2012 May 24. Clin J Am Soc Nephrol. 2012. PMID: 22626962 Free PMC article.
-
Standardized intraoperative application of an absorbable polysaccharide hemostatic powder to reduce the incidence of lymphocele after kidney transplantation - a prospective trial.Transpl Int. 2019 Jan;32(1):59-65. doi: 10.1111/tri.13329. Epub 2018 Sep 3. Transpl Int. 2019. PMID: 30099769 Free PMC article. Clinical Trial.
-
Strategies to overcome the ABO barrier in kidney transplantation.Nat Rev Nephrol. 2015 Dec;11(12):732-47. doi: 10.1038/nrneph.2015.144. Epub 2015 Sep 1. Nat Rev Nephrol. 2015. PMID: 26324199 Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical